Group 1 - The stock of Hongye Futures fell by 1.85% and appeared on the "Dragon and Tiger List," with a cumulative deviation of 20% over three consecutive trading days, indicating significant trading activity from well-known speculators [1] - The top five buying entities on the Dragon and Tiger List collectively purchased 292 million yuan, while the top five selling entities sold 402 million yuan, resulting in a net outflow of 110 million yuan [2] - The largest buying entity, Shen Stock Connect, bought 81.07 million yuan, while the largest selling entity sold 100.02 million yuan, leading to a net outflow of 18.94 million yuan [3] Group 2 - Institutional investors and specific brokerage firms were active in both buying and selling, with notable purchases from institutions totaling 63.25 million yuan and sales amounting to 70.28 million yuan, resulting in a net outflow of 703.51 million yuan [3] - The trading activity indicates a significant interest from institutional and retail investors, with the top five selling entities showing substantial outflows, particularly from East Asia Qianhai Securities [3]

关于下属公司诉讼进展的公告 共 3 页 证券代码：000931 证券简称：中关村 公告编号：2025-069 北京中关村科技发展（控股）股份有限公司 关于下属公司诉讼进展的公告 本公司及董事会全体成员保证信息披露内容的真实、准确和完整，没有虚假 记载、误导性陈述或重大遗漏。 特别提示： 1、案件所处的诉讼阶段：案件一目前二审已判决，案件二双方达成和解。 2、上市公司所处的当事人地位：案件一被告为公司下属公司，案件二原告 为公司下属公司。 3、涉案的金额：总金额人民币 13,106,309.76 元，其中：案件一涉案金额为 人民币 1,107,655.00 元，案件二涉案金额为人民币 11,998,654.76 元。 案件二：久久泰和因与张浩存在销售代理合同纠纷，向北京市海淀区人民法 院提起诉讼，诉讼请求：被告向原告退还佣金共计 11,998,654.76 元、被告承担 诉讼费用。 4、对上市公司损益产生的影响：案件一、案件二将对公司利润产生负面影 响。后续公司将按照法律法规及企业会计准则进行相应会计处理，最终对公司利 润的影响金额以案件执行结果及会计师审计确认后的数据为准。 一、本次诉讼的基本情况 案件一：北 ...

Group 1 - CITIC Construction Investment has received approval from the China Securities Regulatory Commission to issue perpetual subordinated bonds with a total face value of no more than 20 billion yuan [1] - Bluefocus Technology has received a loan commitment of up to 900 million yuan from CITIC Bank for stock repurchase [1] - Huaren Pharmaceutical's subsidiary has received approval for the listing of Bumetanide raw materials, which are used to treat severe heart failure and hypertension emergencies [3] Group 2 - Betta Pharmaceuticals has received approval for the listing of Enasidenib capsules in Macau, aimed at treating ALK-positive locally advanced or metastatic non-small cell lung cancer [4] - Juewei Food plans to use 110 million yuan of idle fundraising for cash management, with an expected annual yield of 1.00%-1.89% [6] - China Huadian has successfully completed the issuance of 1 billion yuan medium-term notes with a coupon rate of 1.95% [9] Group 3 - Fosun Pharma's subsidiary has received a GMP certificate from the Belgian Federal Agency for Medicines and Health Products for the production facilities of two monoclonal antibodies [11] - China Nuclear Engineering has signed a civil engineering contract for the Taishan Nuclear Power Units 3 and 4 [13] - Kanglongda has faced administrative regulatory measures from the Zhejiang Securities Regulatory Bureau due to the failure of performance commitment parties to fulfill compensation obligations [15] Group 4 - Gaoling Information has received three invention patent certificates in the second quarter, covering various technological fields [16] - Weimais plans to use 190 million yuan of excess fundraising to increase capital in its subsidiary for building a new energy vehicle powertrain production base [17] - Huazhong Technology has received a project designation notice from a leading eVTOL manufacturer for the development and supply of an intelligent cockpit multimedia display system [19] Group 5 - Madi Technology expects a net profit of 25 million to 27 million yuan for the first half of 2025, marking a turnaround from a loss in the previous year [19] - Dazhong Mining's subsidiary has obtained a mining license for the Zhouyoufang Iron Mine, increasing production capacity to 6.5 million tons per year [20] - Zhongguancun's subsidiary has had its application for the listing of Arolol hydrochloride tablets accepted by the National Medical Products Administration [21] Group 6 - Tianhong Co. has signed a property management contract worth 15 million yuan with a local company [22] - Dong'an Power has secured nine new market designation agreements in the second quarter, with a projected total sales volume of 1.5 million units [24] - Zhujiang Co. has appointed Zhao Kun as the new deputy general manager [25] Group 7 - Jinyi Industrial has won a bid for a project worth 335 million yuan from the China Railway Shanghai Bureau Group [26] - Kangchen Pharmaceutical has received a clinical trial notification for its innovative drug KC1086, aimed at treating advanced solid tumors [27] - Changhua Group has received a project designation notice from a new energy vehicle company, with an expected total sales amount of 970 million yuan [29] Group 8 - Lingxiao Pump Industry plans to use 60 million yuan of idle funds to purchase financial products [31] - Mould Technology has received a project designation for exterior parts from a well-known North American electric vehicle company, with an expected total sales of 1.236 billion yuan [34] - Fulongma has pre-bid for five sanitation service projects in June, with a total contract amount of 181 million yuan [35] Group 9 - Changchun High-tech plans to issue H-shares and list on the Hong Kong Stock Exchange [36] - *ST Yuancheng is under investigation by the CSRC for suspected false financial disclosures [37] - Beilu Pharmaceutical's subsidiary has received approval for the listing of Iopamidol raw materials [38] Group 10 - Zhejiang Liming's shareholder plans to reduce their stake by up to 2.93% [39] - Zhejiang Liming's actual controller has committed not to reduce their holdings within a year [40] - SAIC Motor reported a total vehicle sales of 2.0526 million units in the first half of 2025, a year-on-year increase of 12.35% [41] Group 11 - Xinhongcheng expects a net profit increase of 50%-70% for the first half of 2025 [42] - Xianhe Co. plans to invest 11 billion yuan in a bamboo pulp paper integrated project [42] - Great Wall Motors reported a total vehicle sales of 569,800 units in the first half of 2025, a year-on-year increase of 1.81% [43] Group 12 - Dongfeng Co. received a government subsidy of 10 million yuan [44] - Zhongke Environmental Protection has acquired two water environmental companies in Guangxi for a total of 353 million yuan [45] - Anji Food's H-share public offering is priced at 60 Hong Kong dollars per share [46]

关于下属公司北京华素盐酸阿罗洛尔片收到国家药品监督管理局《受理通知书》的公告 共 2 页 证券代码：000931 证券简称：中关村 公告编号：2025-068 北京中关村科技发展（控股）股份有限公司 关于下属公司北京华素盐酸阿罗洛尔片收到国家药品监督 管理局《受理通知书》的公告 本公司及董事会全体成员保证信息披露的内容真实、准确、完整，没有虚 假记载、误导性陈述或重大遗漏。 北京中关村科技发展（控股）股份有限公司（以下简称：公司）下属公司 北京华素制药股份有限公司（以下简称：北京华素）于近日收到国家药品监督 管理局（以下简称：国家药监局）签发的《受理通知书》，盐酸阿罗洛尔片（规 格：10mg）上市许可申请获得受理，现将相关情况公告如下： 一、基本信息 药品名称：盐酸阿罗洛尔片 剂型：片剂 规格：10mg 申请事项：境内生产药品注册上市许可 注册分类：化学药品 4 类 申请人：北京华素制药股份有限公司 受理号：CYHS2502307 结论：经审查，决定予以受理。 二、药品其他相关情况 盐酸阿罗洛尔片是一种 α-β 受体阻滞剂，适用于治疗原发性高血压（轻度- 中度）、心绞痛、心动过速性心律失常、原发性震颤。本品进 ...

中关村（000931）公告，下属公司北京华素盐酸阿罗洛尔片(规格：10mg)上市许可申请获得国家药品监 督管理局受理。该药品是一种α-β受体阻滞剂，适用于治疗原发性高血压、心绞痛、心动过速性心律失 常、原发性震颤。目前，境内已有3家仿制药获批上市，除北京华素外，已有4家境内企业提交了上市许 可申请，现正在审评中。盐酸阿罗洛尔片项目已累计投入研发费用609万元。如顺利获批，将对公司经 营业绩产生积极影响。 ...

Group 1 - The Beijing Municipal Science and Technology Commission and Zhongguancun Management Committee announced the application period for the key technology innovation support project for technology-based small and micro enterprises in the Zhongguancun National Independent Innovation Demonstration Zone, which will be open from July 2 to July 31 this year [1] - Eligible applicants must be enterprises in hard technology fields such as new generation information technology, medical health, intelligent manufacturing, new materials, green energy, and energy conservation and environmental protection, registered as national high-tech enterprises or Zhongguancun high-tech enterprises after January 1, 2020 [1] - Enterprises must have fewer than 100 employees and annual revenue below 20 million yuan for the 2024 accounting year, with specific R&D expenditure requirements based on their registration date [1] Group 2 - Applications must be submitted online through the Beijing Science and Technology Plan Comprehensive Management Platform, and offline applications will not be accepted [2] - The Beijing Municipal Science and Technology Commission and Zhongguancun Management Committee emphasized the importance of the authenticity and accuracy of the submitted data and materials, warning against falsification [2] - There will be supervision and inspection of the qualification of funded enterprises before the end of 2025, with the possibility of recovering funds from those that lose their high-tech enterprise status or do not meet support conditions [2]

转自：北京日报客户端 张革表示，经各方面共同推动和努力下，中关村东区改造项目A组团顺利启动实施，后续工作平稳有序 进行，在推进城市更新上探出了新路子、新模式。实施城市更新行动，是推动城市高质量发展、不断满 足人民美好生活需要的重要举措，也是一项系统工程，要认真总结经验，科学谋划工作，完善思路措 施，久久为功推进。要一体推进"好房子、好配套、好物业、好邻里"建设，未雨绸缪系统性解决各类难 题，着力补齐基础设施和公共服务设施短板，更好改善人居环境，强化服务辐射、溢出带动作用。要传 承发展城市文化，保留好建筑风貌和场所文化，再现生机与活力，更好展现海淀城市文化特色和精神气 质。要做深做细群众工作，紧密联系群众思想和工作实际，将利民惠民政策讲清楚、讲通透，及时答疑 解惑回应关切，逐一化解痛点难点问题，把事关百姓切身利益的事情抓实抓好，以实实在在的工作成效 赢得群众的信任和支持。要特别关注群众的生产生活，关心关爱困难群众、特殊群体，切实解决实际困 难和问题。要加强多部门和多专业整体联动，紧盯时间节点，密切协同配合，严把质量和安全关，科学 组织施工，确保项目如期建成投用。 区委常委、副区长马光耀参加。 来源：北京海淀 区 ...

Core Insights - Tianjin Binhai High-tech Zone's Tiankai Huayuan Science and Technology Park is experiencing significant growth and development, attracting numerous high-tech enterprises and innovation platforms [2][3][6] Group 1: Development and Growth - The Tiankai Huayuan Science and Technology Park covers an area of 11.58 square kilometers and has attracted 454 high-growth technology companies in the past year, with 125 of these being from Beijing and Hebei, accounting for nearly 30% of the total [3][6] - The park is recognized as Tianjin's "Zhongguancun," housing major global companies such as Siemens and Toyota, and is part of a broader "one core, two wings, multiple points" development strategy for 2024 [2][6] Group 2: Innovation and Collaboration - The park features 128 research and innovation platforms, 22 national-level incubators, and 16 research centers co-established with universities, fostering a vibrant ecosystem for innovation [2][6] - A three-tier incubation model has been implemented, with a total incubation area of 1.2 million square meters, positioning the park among the top in the nation for incubated enterprises [6][7] Group 3: Technology Transfer and Financial Innovation - The park has introduced a "pay after use" model for technology transfer, which has facilitated the commercialization of 14 technological achievements, promoting collaboration between academia and industry [7][8] - Various payment models, such as "zero threshold fee + milestone payment" and "open licensing + insurance backing," have been successfully implemented to reduce barriers to technology acquisition and accelerate industrialization [8]

Core Insights - The "Tiangong 2.0" robot showcased advanced capabilities in a training ground, demonstrating the progress in robotics technology and its applications in various fields [1] - The Zhongguancun (Yizhuang) International Robot Industry Park has attracted multiple robotics companies, indicating a growing ecosystem for robotics innovation in Beijing [1] Group 1: Robotics Industry Development - The park includes companies such as Ubtech, Hejing Technology, Lingzu Times, and Kuawei Intelligent, covering humanoid robots, medical robots, special robots, and key robot components [1] - The event highlighted the application of robotics technology in industrial, medical, and home life sectors, showcasing robots performing tasks like making coffee, inspecting cars, and assisting in surgeries [1] Group 2: Policy and Innovation - Committee members emphasized the importance of technological self-reliance and collaborative innovation between industry, academia, and research to achieve high-quality development in Beijing [2] - Suggestions were made to strengthen policy guidance and align market needs with core technology development to ensure sustainable growth in the robotics industry [1][2]

"10年前，我们也是一家只有十几人的小微企业。" 中关村生命科学园企业、北京诺诚健华医药科技有 限公司如今已成长为一家在香港和上海两地上市的中型创新药企业。诺诚健华企业传播执行总监陆春华 表示，小微企业发展离不开政策支持，医药行业尤为如此。北京出台促进创新医药产业"32条"，对创新 药企发展有巨大帮助，深入园区的政策宣讲有助于将政策红利转变为企业发展动能，帮助更多小微企业 茁壮成长。 民营经济促进法出台，如何助推绿色生物经济高质量发展？首都民营经济政策宣讲服务团成员、华熙生 物董事长兼总裁赵燕结合自身企业发展情况，讲述对政策的理解，也为小微企业用好用足政策提供有益 借鉴。 转自：北京日报客户端 6月27日是联合国设立的"中小微企业日"。当天，"小微，您好"首都民营经济政策宣讲服务团昌平行活 动在中关村生命科学园举行，向医药健康领域的小微企业宣传解读民营经济促进法，推动产业政策在民 营小微企业落地生根。 活动由市工商联、市发展改革委、市经济和信息化局、昌平区政府、微博党委联合主办。近年来，昌平 区打造医药健康、先进能源、先进制造三大千亿级产业集群，为中小微企业提供了广阔发展空间。目前 全区规模以上中小微型企业已 ...